TENX logo

TENX
Tenax Therapeutics Inc

16,970
Mkt Cap
$256.24M
Volume
360,687.00
52W High
$18.38
52W Low
$4.63
PE Ratio
-11.15
TENX Fundamentals
Price
$14.90
Prev Close
$14.97
Open
$14.99
50D MA
$13.43
Beta
0.41
Avg. Volume
189,942.25
EPS (Annual)
-$1.34
P/B
1.43
Rev/Employee
$0.00
$380.49
Loading...
Loading...
News
all
press releases
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Cantor Fitzgerald Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX)
Cantor Fitzgerald began coverage on shares of Tenax Therapeutics in a research report on Tuesday. They set an "overweight" rating and a $35.00 target price on the stock...
MarketBeat·11d ago
News Placeholder
Boothbay Fund Management LLC Purchases Shares of 352,206 Tenax Therapeutics, Inc. $TENX
Boothbay Fund Management LLC acquired a new position in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX - Free Report) in the third quarter, according to its most recent Form 13F filing with the...
MarketBeat·11d ago
News Placeholder
Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Tuesday
Tenax Therapeutics (NASDAQ:TENX) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 24. (View Earnings Report at...
MarketBeat·11d ago
News Placeholder
Guggenheim Issues Positive Forecast for Tenax Therapeutics (NASDAQ:TENX) Stock Price
Guggenheim raised their price target on shares of Tenax Therapeutics from $25.00 to $34.00 and gave the stock a "buy" rating in a report on Monday...
MarketBeat·12d ago
News Placeholder
What is Lifesci Capital's Forecast for TENX Q1 Earnings?
Tenax Therapeutics, Inc. (NASDAQ:TENX - Free Report) - Equities researchers at Lifesci Capital issued their Q1 2026 earnings estimates for Tenax Therapeutics in a report released on Thursday, March...
MarketBeat·12d ago
News Placeholder
Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the stock, MarketBeat.com reports. One...
MarketBeat·15d ago
News Placeholder
Tenax Therapeutics (NASDAQ:TENX) Shares Cross Above 200 Day Moving Average - Here's What Happened
Tenax Therapeutics (NASDAQ:TENX) Share Price Passes Above 200 Day Moving Average - Here's Why...
MarketBeat·24d ago
News Placeholder
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?
Tenax Therapeutics (NASDAQ:TENX) Share Price Crosses Above 200 Day Moving Average - What's Next...
MarketBeat·1mo ago
News Placeholder
Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim Conference
Executives from Tenax Therapeutics (NASDAQ:TENX) outlined progress on the company's Phase III development program for levosimendan in pulmonary hypertension associated with heart failure with...
MarketBeat·1mo ago
<
1
2
...
>

Latest TENX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.